| (Values in U.S. Thousands) | Dec, 2017 | Dec, 2016 | Dec, 2015 | Dec, 2014 | Dec, 2013 |
| Sales | 720 | 440 | 940 | 860 | 370 |
| Sales Growth | +63.64% | -53.19% | +9.30% | +132.43% | unch |
| Net Income | -1,940 | -4,450 | -2,700 | -1,940 | -3,080 |
| Net Income Growth | +56.40% | -64.81% | -39.18% | +37.01% | +12.75% |
Uluru Inc (ULUR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology.
Fiscal Year End Date: 12/31